Everything below concerns AOD-9604. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
== In plants == As it does in human cells, glutathione reductase helps to protect plant cells from reactive oxygen species. In plants, reduced glutathione participates in the glutathione-ascorbate cycle in which reduced glutathione reduces dehydroascorbate, a reactive byproduct of the reduction of hydrogen peroxide. In particular, glutathione reductase contributes to plants' response to abiotic stress. The enzyme's activity has been shown to be modulated in response to metals, metalloids, salinity, drought, UV radiation and heat induced stress.
Amphetamine – systematic reviews and meta-analyses report that low-dose amphetamine may improve cognitive functions (e.g. inhibitory control, episodic memory, working memory, and aspects of attention) in healthy people and individuals with ADHD. A 2014 systematic review noted that low doses of amphetamine may also improve memory consolidation, in turn leading to improved recall of information in non-ADHD youth. It may also improve task salience (motivation to perform a task) and performance on tedious tasks that require a high degree of effort. Caffeine – a meta-analysis found a general increase in alertness and attention after consuming caffeine. Eugeroics (armodafinil and modafinil) – classified as "wakefulness-promoting agents"; modafinil may increase alertness, particularly in sleep-deprived individuals, and may improve reasoning and problem solving in non-ADHD youth. In a systematic review of small, preliminary studies where the effects of modafinil were examined, when simple psychometric assessments were considered, modafinil intake enhanced executive function. Modafinil does not seem to improve mood or motivation in sleep-deprived or non-sleep-deprived individuals. Methylphenidate – a benzylpiperidine derivative that may improve working memory, episodic memory, and inhibitory control; aspects of attention; and planning latency in healthy people. It also may improve task salience and performance on tedious tasks. At above optimal doses, methylphenidate has off–target effects that decrease learning.
== Further reading == World Health Organization publications: Safety and nutritional adequacy of irradiated food, WHO, Geneva, 1994 High-dose irradiation: Wholesomeness of food irradiated with doses above 10 kGy, WHO, Geneva, 1999, Technical Report Series No. 890 Facts about Food Irradiation, A series of Fact Sheets from the International Consultative Group on Food Irradiation (ICGFI), 1999, IAEA, Vienna, Austria at the Wayback Machine (archived 2006-03-16) Diehl, J.F., Safety of irradiated foods, Marcel Dekker, N.Y., 1995 (2. ed.) Satin, M., Food irradiation, Technomic, Lancaster, 1996 (2. ed.) Urbain, W.M., Food irradiation, Academic Press, Orlando, 1986 Molins, R. (ed.), Food irradiation – Principles and applications, Wiley Interscience, N.Y., 2001 Sommers, C.H. and Fan, X. (eds.), Food Irradiation Research and Technology, Blackwell Publishing, Ames, IA, 2006 The Food That Would Last Forever : Understanding the Dangers of Food Irradiation, by Gary Gibbs, Garden City Park, N.Y. : Avery Pub. Group, c1993 anon., Food Irradiation: Available Research Indicates That Benefits Outweigh Risks, RCED-00-217, August 24, 2000, Government Accountability Office, United States General Accounting Office, Resources, Community, and Economic Development Division, Washington, D.C. 20548 "Food Irradiation" Farkas, József; Mohácsi-Farkas, Csilla (March 2011). "History and future of food irradiation". Trends in Food Science & Technology. 22 (2–3): 121–126. doi:10.1016/j.tifs.2010.04.002.
Sources: en.wikipedia.org
== Properties == The alcohol dehydrogenases comprise a group of several isozymes that catalyse the oxidation of primary and secondary alcohols to aldehydes and ketones, respectively, and also can catalyse the reverse reaction. In mammals this is a redox (reduction/oxidation) reaction involving the coenzyme nicotinamide adenine dinucleotide (NAD+).
These independent courts found their existence threatened by warlords, necessitating cooperation which resulted in their unification by 2000. The Islamic Courts Union (ICU) was a broad-based organization comprising various courts with diverse goals, from national political ambitions to local dispute resolution and propagation of Islam. Due to Islam's central role in Somali society, the initiative gained significant popularity and acceptance, along with substantial financial support from the Somali business community, as it originated from the grassroots level, built legitimacy through religious solidarity, addressed local security concerns, and demonstrated a commitment to restoring public order.
=== Etymology === The English word is from Classical Nahuatl chīlli with the same meaning. The name of the plant is unrelated to that of the country Chile. While pepper originally meant the genus Piper, not Capsicum, the Oxford English Dictionary and Merriam-Webster record both usages. The three primary spellings are chili (common in North America), chile (Central America and parts of the US) and chilli (United Kingdom and former British colonies). The specific dish name "chili con carne" is normally written with one "l" in both American and British English.
The pharmacokinetics of progesterone are dependent on its route of administration. The medication is approved in the form of oil-filled capsules containing micronized progesterone for oral administration, termed "oral micronized progesterone" ("OMP") or simply "oral progesterone". It is also available in the form of vaginal or rectal suppositories, vaginal gels, oil solutions for intramuscular injection, and aqueous solutions for subcutaneous injection, among others. Routes of administration that progesterone has been used include oral, intranasal, transdermal, vaginal, rectal, intramuscular, subcutaneous, and intravenous injection. Oral progesterone has been found to be inferior to vaginal and intramuscular progesterone in terms of absorption (low) and clearance rate (rapid). Vaginal progesterone is available in the forms of progesterone gel, rings, and suppositories or pessaries. Advantages of intravaginal progesterone over oral administration include high bioavailability, rapid absorption, avoidance of first-pass metabolism, sustained plasma concentrations, and a local endometrial effect, while advantages of intravaginal progesterone relative to intramuscular injection include greater convenience and lack of injection site pain. Intranasal progesterone as a nasal spray is effective in achieving therapeutic levels, and was not associated with nasal irritation, but was associated with an unpleasant taste of the spray. Rectal, intramuscular, and intravenous routes may be inconvenient, especially for long-term treatment.
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.